Diagnosis of prostate cancer by the combined molecular imaging focused on [18F]choline-PET

随着国家人口的老龄化，前列腺癌的发病率预计将在未来增加。我们用示踪剂[18F]氟胆碱(FCH)对71例高度怀疑患有前列腺癌的患者和8例有复发嫌疑的患者进行了PET检查，这些患者后来进行了病理检查。FCH-PET的诊断性能与MRI相当，对远处转移的诊断几乎是准确的，需要FCH-PET寻找复发的患者比预期的要少得多。因此，在三年的研究期间，我们很难对FCH-PET对前列腺癌复发的诊断能力进行分析，并将继续获得更多需要诊断的患者，无论是否有复发。我们经历了两例(79次扫描中)意外的肺癌被FCH-PET意外发现。

As the country's population grows older, increase of prostate cancer is expected in future. We performed PET with the tracer [18F] fluorocholine (FCh) for 71 patients with strong suspicion of having prostate cancer, who were pathologically examined later, and for 8 patients with a suspicion of recurrence. The diagnostic performance of FCh-PET was equivalent to that of MRI, and the diagnosis of the distant metastasis by FCh-PET was almost good.There was much little number of patients requiring the FCh-PET for searching recurrence than anticipated. So we could hardly perform analysis for diagnostic ability of FCh-PET on the recurrence of prostate cancer during the three year study period, and will continue to get more patients who requires to be diagnosed whether there is recurrence or not. We experienced two cases (out of 79 scans) with unexpected lung cancer incidentally detected by FCh-PET.